These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30235536)

  • 1. Investigation of the Safety Profiles of Japanese Clinical Trials.
    Kanmuri K; Narukawa M
    Ther Innov Regul Sci; 2014 May; 48(3):308-315. PubMed ID: 30235536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of Characteristics of Japanese Clinical Trials in Terms of Data Variability.
    Kanmuri K; Narukawa M
    Ther Innov Regul Sci; 2013 Jul; 47(4):430-437. PubMed ID: 30235524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Associated with Inclusion of Japan in Phase I Multiregional Clinical Trials in Oncology.
    Maki A; Narukawa M
    Ther Innov Regul Sci; 2024 Jul; 58(4):766-772. PubMed ID: 38652349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Asian Participation in Multi-regional Clinical Trials Reviewed for Drug Approval in Japan: Opportunities for Collaboration Between South-East Asia, East Asia, and Japan.
    Aoi Y; Kato Y; Asano K; Otsubo Y; Uyama Y
    Ther Innov Regul Sci; 2023 Nov; 57(6):1298-1303. PubMed ID: 37587270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Future Drug Development Lag in Japan Based on an Analysis of Multiregional Clinical Trials in the US, Europe, and East Asia.
    Noguchi A; Hanaoka H; Uyama Y
    Ther Innov Regul Sci; 2022 May; 56(3):523-529. PubMed ID: 35181842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of safety outcomes of anticancer drugs in Japanese and non-Japanese patients in multi-regional clinical trials: meta-analysis of safety profiles.
    Tamai T; Narukawa M
    Invest New Drugs; 2023 Jun; 41(3):483-492. PubMed ID: 37162707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Analysis of Japanese Patients Enrolled in Multiregional Clinical Trials in Oncology.
    Hirakawa A; Kinoshita F
    Ther Innov Regul Sci; 2017 Mar; 51(2):207-211. PubMed ID: 30231713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of global versus Asian clinical trial strategies supportive of registration of drugs in Japan.
    Shirotani M; Kurokawa T; Chiba K
    J Clin Pharmacol; 2014 Jul; 54(7):753-64. PubMed ID: 24496890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Drug Lags in Development Initiation, New Drug Application and Approval Between Japan and the USA and the Impact of Local Versus Multi-regional Clinical Trials.
    Ushijima S; Matsumaru N; Tsukamoto K
    Pharmaceut Med; 2021 Jul; 35(4):253-260. PubMed ID: 34291425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches to Japanese dose evaluation in global drug development: factors that generate different dosages between Japan and the United States.
    Nakashima K; Narukawa M; Takeuchi M
    Clin Pharmacol Ther; 2011 Dec; 90(6):836-43. PubMed ID: 22048222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International oncology drug approvals for multiregional or single-country clinical trials: A systematic review.
    Zhang M; Onakpoya I; Rupalla K
    Front Med (Lausanne); 2022; 9():1084980. PubMed ID: 36590932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploratory Analysis of Drug Lag in New Oncology Drugs Between Japan and the US.
    Maki A; Narukawa M
    Ther Innov Regul Sci; 2023 Jul; 57(4):671-677. PubMed ID: 36966205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid Globalization of Medical Device Clinical Development Programs in Japan　- The Case of Drug-Eluting Stents.
    Murakami M; Suzuki Y; Tominaga T
    Circ J; 2018 Feb; 82(3):636-643. PubMed ID: 28883226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
    Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
    Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan.
    Rokuda M; Matsumaru N; Tsukamoto K
    Clin Ther; 2018 Feb; 40(2):284-295. PubMed ID: 29361305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical issues and lessons learned from multi-regional clinical trials via case examples: a Japanese perspective.
    Ando Y; Hamasaki T
    Pharm Stat; 2010; 9(3):190-200. PubMed ID: 20737442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiregional clinical trials: Japanese perspective on drug development strategy and sample size for Japanese subjects.
    Ando Y; Uyama Y
    J Biopharm Stat; 2012 Sep; 22(5):977-87. PubMed ID: 22946944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishing consistency across all regions in a multi-regional clinical trial.
    Tsou HH; James Hung HM; Chen YM; Huang WS; Chang WJ; Hsiao CF
    Pharm Stat; 2012; 11(4):295-9. PubMed ID: 22504851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
    Ekimoto H
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.